StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| December 23, 2024 | Timely Disclosure Information | StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy |
|---|---|---|
| December 12, 2024 | Financial Results | [Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024 [Japanese GAAP] |
| December 12, 2024 | Timely Disclosure Information | [Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy” |
| December 11, 2024 | Timely Disclosure Information | StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
| December 09, 2024 | Timely Disclosure Information | StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
